News

Clinical Data with ImCheck’s ICT01 to be Presented at AACR: Positive Results Observed on Safety, Activation of Gamma 9 Delta 2 T Cells and Anti-tumor Immune Response

Details

ICT01 activates γ9δ2 T cells that rapidly migrate out of the circulation and secrete IFNγ and TNFα leading to an expanded immune system activation. 

UroMems Completes €23 Million Series B Financing

Details

UroMems, announced that it has raised an additional €7 million in a second tranche of its previously announced Series B financing round completed in May 2020.

Immatics Presents Data Update on Dose Escalation from Ongoing ACTengine® Cell Therapy Programs

Details

Immatics announced a clinical data update from the dose escalation cohorts of the company’s ongoing Phase 1 trials for its engineered Adoptive Cell Therapy approach (also known as TCR-T). 

  1. Partner Therapeutics Announces Partnership with SIRS Therapeutics and F4 Pharma to Explore Potential Uses for FX06 in Biodefense Applications
  2. eGenesis Announces $125 Million Series C Financing
  3. Creative Balloons closes €15 million growth financing and appoints Frank Gehres as CEO
  4. ONWARD Announces Publication in Nature Demonstrating Blood Pressure Stabilization in People with Spinal Cord Injury
© Wellington Partners, 2021.